ホーム > 市場調査レポート > 医薬品

表紙：血漿プロテアーゼC1阻害剤治療の世界市場：薬剤タイプ別、投与量別、流通チャネル別、地域別 - 規模、シェア、展望、機会分析（2022年～2028年）

市場調査レポート

商品コード

1085743

血漿プロテアーゼC1阻害剤治療の世界市場：薬剤タイプ別、投与量別、流通チャネル別、地域別 - 規模、シェア、展望、機会分析（2022年～2028年）

Plasma Protease C1-inhibitor Treatment Market, by Drug Type, by Dosage, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: 2022年05月13日 | 発行: Coherent Market Insights

| ページ情報: 英文 186 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 705,420円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,097,320円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,567,600円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
目次

概要

サンプル依頼リストに入れる

遺伝性血管性浮腫（HAE）治療において血漿由来のC1エステラーゼ阻害製品を使用する傾向が高まっていることから、世界の血漿プロテアーゼC1阻害剤治療市場の成長を牽引すると予想されます。

当レポートでは、世界の血漿プロテアーゼC1阻害剤治療市場について調査分析し、市場促進要因と抑制要因、市場機会、COVID-19の影響、薬剤タイプ・投与量・流通チャネル・地域別の市場分析、競合情勢などを提供しています。

企業プロファイル
- CSL Behring LLC.
- 臨床試験フェーズのポートフォリオ
- Takeda Pharmaceutical Company Limited
- 臨床試験フェーズのポートフォリオ
- Ionis Pharmaceuticals, Inc.
- 臨床試験フェーズのポートフォリオ
- Pharming Technologies B.V.
- 臨床試験フェーズのポートフォリオ
- Centogene AG
- 臨床試験フェーズのポートフォリオ
- BioCryst Pharmaceuticals
- 臨床試験フェーズのポートフォリオ
- KalVista Pharmaceuticals, Inc.
- 臨床試験フェーズのポートフォリオ

Product Code: CMI4262

C1-inhibitor (C1-H) belongs to the superfamily of serine protease inhibitors. C1-inhibitors controls the activation of the C1 complex. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. It also plays an important role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis, and generation of kinins. It is the most efficient inhibitor of FXIIa factors and also inhibits chymotrypsin and kallikrein.

Market Dynamics

Hereditary angioedema (HAE) is the disease condition characterized by the C1 esterase inhibitor deficiency. According to reported data by National Center for Biotechnology Information in 2013, the estimated prevalence of HAE in the general population is between 1 in 10,000 and 1 in 150,000 individuals worldwide. Cinryze, a pharmaceutical-grade C1-inhibitor, was approved by U.S.FDA for the treatment of HAE in 2008. Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product; it has been approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. Thus, the increasing trend of using plasma-derived C1 esterase inhibitor products in HAE treatment is expected to drive growth of the global plasma protease C1-inhibitor treatment market.

Key features of the study:

This report provides in-depth analysis of the global plasma protease C1-inhibitor treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global plasma protease C1-inhibitor treatment market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans

Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.

Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics

The global plasma protease C1-inhibitor treatment market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protease C1-inhibitor treatment market.

Detailed Segmentation:

Global Plasma Protease C1-inhibitor Treatment Market, By Drug Type:
- C1-inhibitors
- Kallikrein Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
Global Plasma Protease C1-inhibitor Treatment Market, By Dosage:
- Lyophilized
- Injectable
Global Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Plasma Protease C1-inhibitor Treatment Market, By Region:
- North America
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - U.S.
  - Canada
- Latin America
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country/Region:
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles:
- CSL Behring LLC *
  - Company Overview
  - Clinical Trial Phase Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Takeda Pharmaceutical Company Limited
- Ionis Pharmaceuticals, Inc.
- Pharming Technologies B.V.
- Centogene AG
- BioCryst Pharmaceuticals
- KalVista Pharmaceuticals, Inc.

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Dosage
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Drivers
Restraints
Impact Analysis
Market Opportunities
Collaboration and acquisition

4. Plasma Protease C1-inhibitor Treatment Market - Impact of COVID-19 Pandemic

Post COVID-19 Impact
COVID-19 Impact on Research and Development Activities
Demand and Supply Analysis
Overall impact on manufacturing industry

5. Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
- C1-inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Kallikrein Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Selective Bradykinin B2 Receptor Antagonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
- Lyophilized
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

8. Plasma Protease C1-inhibitor Treatment Market, By Region, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, By Country, 2022 and 2028 (%)
Y-o-Y Growth Analysis, For Countries, 2017 - 2028
North America
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.S.
- Canada
Latin America
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
- South Africa
- Central Africa
- North Africa

9. Competitive Landscape

Company Profiles
CSL Behring LLC.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Takeda Pharmaceutical Company Limited
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Ionis Pharmaceuticals, Inc.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Pharming Technologies B.V.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Centogene AG
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
BioCryst Pharmaceuticals
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
KalVista Pharmaceuticals, Inc.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies

Browse 32 market data tables and 30 figures on " Plasma Protease C1-inhibitor Treatment Market - Global forecast to 2028".

ライセンス / 価格

PDF (Single User License)

USD 4,500 705,420円

PDF (Multi User License)

USD 7,000 1,097,320円

PDF (Enterprise User License)

USD 10,000 1,567,600円

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

お電話でのお問い合わせ

044-952-0102

( 土日・祝日を除く )

血漿由来医薬品

血漿プロテアーゼC1阻害剤治療の世界市場：薬剤タイプ別、投与量別、流通チャネル別、地域別 - 規模、シェア、展望、機会分析（2022年～2028年）

Plasma Protease C1-inhibitor Treatment Market, by Drug Type, by Dosage, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場の範囲

第3章市場力学・規制・動向分析

第4章血漿プロテアーゼC1阻害剤治療市場：COVID-19流行の影響

第5章血漿プロテアーゼC1阻害剤治療市場：薬剤タイプ別（2017年～2028年）

第6章血漿プロテアーゼC1阻害剤治療市場：投与量別（2017年～2028年）

第7章血漿プロテアーゼC1阻害剤治療市場：流通チャネル別（2017年～2028年）

第8章血漿プロテアーゼC1阻害剤治療市場：地域別（2017年～2028年）

第9章競合情勢

Market Dynamics

Key features of the study:

Detailed Segmentation:

"" marked represents similar segmentation in other categories in the respective section.*

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Plasma Protease C1-inhibitor Treatment Market - Impact of COVID-19 Pandemic

5. Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2017 - 2028 (US$ Mn)

6. Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2017 - 2028 (US$ Mn)

7. Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

8. Plasma Protease C1-inhibitor Treatment Market, By Region, 2017 - 2028 (US$ Mn)

9. Competitive Landscape

血漿プロテアーゼC1阻害剤治療の世界市場：薬剤タイプ別、投与量別、流通チャネル別、地域別 - 規模、シェア、展望、機会分析（2022年～2028年）

Plasma Protease C1-inhibitor Treatment Market, by Drug Type, by Dosage, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場の範囲

第3章 市場力学・規制・動向分析

第4章 血漿プロテアーゼC1阻害剤治療市場：COVID-19流行の影響

第5章 血漿プロテアーゼC1阻害剤治療市場：薬剤タイプ別（2017年～2028年）

第6章 血漿プロテアーゼC1阻害剤治療市場：投与量別（2017年～2028年）

第7章 血漿プロテアーゼC1阻害剤治療市場：流通チャネル別（2017年～2028年）

第8章 血漿プロテアーゼC1阻害剤治療市場：地域別（2017年～2028年）

第9章 競合情勢

Market Dynamics

Key features of the study:

Detailed Segmentation:

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Plasma Protease C1-inhibitor Treatment Market - Impact of COVID-19 Pandemic

5. Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2017 - 2028 (US$ Mn)

6. Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2017 - 2028 (US$ Mn)

7. Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

8. Plasma Protease C1-inhibitor Treatment Market, By Region, 2017 - 2028 (US$ Mn)

9. Competitive Landscape

第1章調査目的・前提条件

第2章市場の範囲

第3章市場力学・規制・動向分析

第4章血漿プロテアーゼC1阻害剤治療市場：COVID-19流行の影響

第5章血漿プロテアーゼC1阻害剤治療市場：薬剤タイプ別（2017年～2028年）

第6章血漿プロテアーゼC1阻害剤治療市場：投与量別（2017年～2028年）

第7章血漿プロテアーゼC1阻害剤治療市場：流通チャネル別（2017年～2028年）

第8章血漿プロテアーゼC1阻害剤治療市場：地域別（2017年～2028年）

第9章競合情勢

"" marked represents similar segmentation in other categories in the respective section.*